Main Industry
Biotechnology
Main Product/Service
The 619 Protein Drug Platform is a specialized system for developing protein-based therapeutics, focusing on harnessing naturally sourced proteins with unique functions to create drug candidates with reduced or minimal side effects for applications in cancer, degenerative central nervous system diseases, and regenerative medicine.
Founded Year
2024
Unified Business No.
93555813
Status
Active
Number of Employees
5
Total Paid-in
Capital
2,100,000 (NT$)
Location of Company
Taiwan
, Yunlin County
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Currently, most protein drug development relies on synthetic proteins, which are effective but often come with significant side effects. Our goal is to provide naturally sourced proteins as raw materials for protein drugs with low or even no side effects. Nexgen leverages a unique protein extraction and purification technology to obtain distinctive proteins from natural plants and animals, and, based on the diverse functions of these proteins, has expanded them into a protein drug candidate platform targeting cancer, degenerative central nervous system diseases, and regenerative medicine.
